PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.

Science Translational Medicine
Otto KaukoJukka Westermarck

Abstract

Kinase inhibitor resistance constitutes a major unresolved clinical challenge in cancer. Furthermore, the role of serine/threonine phosphatase deregulation as a potential cause for resistance to kinase inhibitors has not been thoroughly addressed. We characterize protein phosphatase 2A (PP2A) activity as a global determinant of KRAS-mutant lung cancer cell resistance across a library of >200 kinase inhibitors. The results show that PP2A activity modulation alters cancer cell sensitivities to a large number of kinase inhibitors. Specifically, PP2A inhibition ablated mitogen-activated protein kinase kinase (MEK) inhibitor response through the collateral activation of AKT/mammalian target of rapamycin (mTOR) signaling. Combination of mTOR and MEK inhibitors induced cytotoxicity in PP2A-inhibited cells, but even this drug combination could not abrogate MYC up-regulation in PP2A-inhibited cells. Treatment with an orally bioavailable small-molecule activator of PP2A DT-061, in combination with the MEK inhibitor AZD6244, resulted in suppression of both p-AKT and MYC, as well as tumor regression in two KRAS-driven lung cancer mouse models. DT-061 therapy also abrogated MYC-driven tumorigenesis. These data demonstrate that PP2A deregula...Continue Reading

References

Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·R T PetersonS L Schreiber
Mar 9, 2002·Molecular and Cellular Biology·William C HahnRobert A Weinberg
Aug 25, 2004·Cancer Cell·Annapoorni RangarajanRobert A Weinberg
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Jul 17, 2007·Cell·Melissa R JunttilaJukka Westermarck
Nov 6, 2007·Nucleic Acids Research·Rune LindingTony Pawson
Nov 17, 2007·Proceedings of the National Academy of Sciences of the United States of America·Shaida AndrabiBrian Schaffhausen
May 28, 2009·Journal of the National Cancer Institute·Anchit KhannaAri Ristimäki
Sep 16, 2010·Annals of Surgical Oncology·Qian-Ze DongEn-Hua Wang
May 4, 2013·The Lancet Oncology·Danilo Perrotti, Paolo Neviani
Dec 24, 2013·Pharmacology & Therapeutics·Todd M PittsErica L Bradshaw-Pierce
Jan 10, 2014·The Journal of Clinical Investigation·Alejandro GutierrezJon C Aster
Mar 5, 2014·Cold Spring Harbor Perspectives in Medicine·Amy S Farrell, Rosalie C Sears
Jun 14, 2014·Proceedings of the National Academy of Sciences of the United States of America·Mahnaz JanghorbanRosalie C Sears
Sep 24, 2015·Genes, Chromosomes & Cancer·Johannes RoutilaSami Ventelä
Aug 4, 2016·Cancer Investigation·Ioannis Ntanasis-StathopoulosElias A Kotteas
Sep 28, 2016·Cancer Research·Amanpreet KaurJukka Westermarck
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael P Smith, Claudia Wellbrock
Dec 4, 2016·Biochemical Society Transactions·Amanpreet Kaur, Jukka Westermarck
Feb 9, 2017·EMBO Reports·Jiao WangJukka Westermarck
May 16, 2017·The Journal of Clinical Investigation·Jaya SangodkarGoutham Narla
Oct 20, 2017·Cancer Research·Ward SentsVeerle Janssens
Nov 7, 2017·The International Journal of Biochemistry & Cell Biology·Caitlin M O'ConnorGoutham Narla
Dec 16, 2017·Journal of the National Cancer Institute·Ariadna TibauEitan Amir
Jan 23, 2018·The International Journal of Biochemistry & Cell Biology·Otto Kauko, Jukka Westermarck

❮ Previous
Next ❯

Citations

Feb 6, 2019·The Journal of Clinical Investigation·Shaikamjad UmesalmaDawn E Quelle
Dec 12, 2019·The Journal of Biological Chemistry·Caroline C FarringtonGoutham Narla
Sep 25, 2019·Current Drug Targets·Kening LiDong-Qing Wei
May 12, 2020·Medicinal Research Reviews·Shalini BajajY C Mayur
Jun 20, 2019·Frontiers in Oncology·Michiel Remmerie, Veerle Janssens
Aug 15, 2018·International Journal of Molecular Sciences·Michiel Remmerie, Veerle Janssens
Mar 19, 2019·Frontiers in Oncology·Corina N A M van den HeuvelWilliam P J Leenders
Aug 9, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Brittany L Allen-Petersen, Rosalie C Sears
Sep 22, 2019·Oncogene·Caitlin M O'ConnorGoutham Narla
Mar 13, 2020·JCI Insight·Esra MeidanGeorge C Tsokos
Jun 6, 2019·Molecular Cancer Research : MCR·Erika ParasidoChris Albanese
Aug 30, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sandra Ortiz-CuaranDavid Planchard
Apr 9, 2021·Science Translational Medicine·Julia P VainonenJukka Westermarck
Apr 22, 2020·Cell·Daniel LeonardGoutham Narla
Mar 7, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eleonora MäkeläJukka Westermarck
Jun 23, 2021·Journal of Medicinal Chemistry·Qiuyue ZhangLei Wang
Jul 25, 2021·Journal of Hematology & Oncology·Kun ChenPeng Wang
Jul 15, 2020·Cancer Cell·Kari J Kurppa, Jukka Westermarck
Jul 29, 2021·The Biochemical Journal·Majid MomenyJukka Westermarck
Jun 20, 2021·Cancer Research·Anni LaineJukka Westermarck
Sep 12, 2021·Nature Reviews. Clinical Oncology·Renumathy DhanasekaranDean W Felsher
Sep 25, 2021·EMBO Reports·David Maria HollensteinWolfgang Reiter
Oct 7, 2021·Oncogene·Lenka KyjacovaJonathan P Sleeman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.